SVB Wealth LLC Boosts Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

SVB Wealth LLC raised its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,320 shares of the medical equipment provider’s stock after acquiring an additional 174 shares during the period. SVB Wealth LLC’s holdings in Zimmer Biomet were worth $1,256,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. PFG Advisors lifted its position in Zimmer Biomet by 4.6% during the fourth quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock worth $231,000 after buying an additional 84 shares in the last quarter. Bradley Foster & Sargent Inc. CT increased its stake in shares of Zimmer Biomet by 1.3% in the 4th quarter. Bradley Foster & Sargent Inc. CT now owns 6,452 shares of the medical equipment provider’s stock worth $823,000 after acquiring an additional 85 shares during the last quarter. Quent Capital LLC increased its stake in shares of Zimmer Biomet by 21.6% in the 4th quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after acquiring an additional 92 shares during the last quarter. Pinnacle Associates Ltd. increased its stake in shares of Zimmer Biomet by 5.0% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider’s stock worth $227,000 after acquiring an additional 97 shares during the last quarter. Finally, Financial Advocates Investment Management increased its stake in shares of Zimmer Biomet by 3.8% in the 3rd quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider’s stock worth $295,000 after acquiring an additional 97 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the transaction, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.95% of the stock is owned by insiders.

Zimmer Biomet Price Performance

ZBH stock opened at $119.41 on Friday. The business’s 50-day moving average is $126.39 and its two-hundred day moving average is $119.10. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.61 and a quick ratio of 0.78. The firm has a market capitalization of $24.53 billion, a P/E ratio of 24.42, a P/E/G ratio of 2.23 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $149.25.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The firm had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. During the same quarter last year, the company earned $1.88 earnings per share. The firm’s revenue was up 6.3% compared to the same quarter last year. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.80%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ZBH shares. Barclays raised their target price on Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research note on Monday, February 12th. TheStreet raised Zimmer Biomet from a “c” rating to a “b-” rating in a research note on Thursday, February 8th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 9th. Raymond James upped their target price on shares of Zimmer Biomet from $133.00 to $137.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Finally, Evercore ISI lifted their price target on shares of Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average price target of $139.39.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.